Shots: Dicerna will receive $100M upfront plus ~$350M as development and commercialization milestones with tiered royalties and equity investment of $100M Lilly will get hold of Dicerna’s GalXC RNAi technology as well as development and commercialization rights to new developed drugs in fields of cardio-metabolic diseases, neurodegeneration and pain Dicerna’s GalXC RNAi technology is an […]Read More
